Reviva Pharmaceuticals Holdings Inc. Cash Flow-to-Debt Ratio
Reviva Pharmaceuticals Holdings Inc. cash flow-to-debt ratio. Reviva Pharmaceuticals Holdings Inc. (RVPH) has a Cash Flow-to-Debt Ratio of -1.00x as of June 2026, meaning its operating cash flow of $-5.92 Trillion could theoretically repay -1% of its total liabilities ($5.93 Trillion) in one year. Check Reviva Pharmaceuticals Holdings Inc. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Reviva Pharmaceuticals Holdings Inc. (2018–2025)
Cash flow-to-debt ratio of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2025. Historical debt coverage capacity for Reviva Pharmaceuticals Holdings Inc. across 8 annual periods. Check RVPH cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Reviva Pharmaceuticals Holdings Inc. Cash Flow-to-Debt Ratio by Year (2018–2025)
Reviva Pharmaceuticals Holdings Inc. cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Reviva Pharmaceuticals Holdings Inc.. For the full cash flow conversion analysis, see Reviva Pharmaceuticals Holdings Inc. cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.38x | $-24.59 Million | $7.28 Million | ▼ -48.0% |
| 2024 | -2.28x | $-33.54 Million | $14.69 Million | ▼ -45.0% |
| 2023 | -1.58x | $-28.32 Million | $17.98 Million | ▲ +12.5% |
| 2022 | -1.80x | $-18.96 Million | $10.53 Million | ▲ +54.1% |
| 2021 | -3.93x | $-10.67 Million | $2.72 Million | ▼ -218.2% |
| 2020 | -1.23x | $-4.07 Million | $3.30 Million | ▼ -3748.1% |
| 2019 | -0.03x | $-218.44K | $6.81 Million | ▲ +81.8% |
| 2018 | -0.18x | $-1.07 Million | $6.09 Million | — |